A hell of a jackpot.

US pharmaceutical group Pfizer said on Tuesday it expected to sell 1.6 billion doses of its anti-Covid vaccine, developed in partnership with BioNTech, in 2021. The sale is estimated at around $ 26 billion, or much more than expected before.

Indeed, the company had announced at the end of February that it would sell about 15 billion dollars of serum over the whole year.

It has since signed other contracts for 2021, with the European Commission in particular, and said on Tuesday it had concluded agreements with Canada and Israel to provide vaccines beyond 2021. Pfizer said in a press release "to be in the process of negotiate similar potential contracts with many other countries ”.

430 million doses sent to 91 countries

As of May 3, the group had already sent around 430 million doses of the vaccine to 91 countries and territories around the world.

Buoyed by the demand for its flagship product, which thus becomes one of the biggest “blockbusters” in the history of pharmacy, the group has significantly raised its forecasts for the year as a whole.

Total revenue in 2021 is expected to reach between $ 70.5 billion and $ 72.5 billion, compared to $ 59.4 billion and $ 61.4 billion previously forecast.

"Solid performance" of the company's activities

Pfizer is also betting on an adjusted earnings per share of between 3.55 and 3.65 dollars, against 3.10 to 3.20 dollars previously.

This profit is the indicator monitored by financial circles to measure a company's profitability because it does not take into account elements external to performance such as taxes and certain costs.

The update of these forecasts reflects new expectations for the anti-Covid vaccine, as well as “the solid performance” of the rest of the company's activities.

It also takes into account "the additional expenditure on research and development on vaccination against Covid-19 but also on other products in development based on messenger RNA and on anti-virals against Covid-19", specifies Pfizer.

Lab revenue jumped 45%

In the first quarter, the company has already sold $ 3.5 billion of the serum, on which it expects to generate a pre-tax margin of around 25% to 30%.

The other group activities also grew, its turnover excluding anti-Covid vaccine increasing by 8%.

Including the vaccine, the lab's revenue jumped 45% to $ 14.6 billion, well above analysts' forecasts ($ 13.6 billion).

Its net profit also soared 45% to $ 4.9 billion.

The stock rose 1.3% in electronic trading before the stock market opened on Wall Street.

Health

Coronavirus: Five cases of myocarditis detected in France in people vaccinated with Pfizer

World

Coronavirus: United States to approve Pfizer vaccine for 12-15 year olds

  • Laboratory

  • Covid 19

  • Coronavirus

  • Anti-covid vaccine

  • Vaccination

  • Health

  • Vaccine

  • Pfizer-BioNTech